electroCore

Electrocore reported record revenue of $9.6 million in Q1 2026, up 43% year‑over‑year, and a gross margin of 87% (+200 basis points). Despite a GAAP net loss of $5.3 million (vs. $3.9 million in Q1 2025), the adjusted EBITDA loss improved to $2.3 million. The company attributed higher losses to one‑time expenses related to the leadership change, confirmed its full‑year guidance of roughly 30% revenue growth, and expects an additional $9–10 million in revenue versus 2025. Management emphasizes operational efficiency but flags cash burn as well as regulatory and market‑penetration risks as key challenges. » More on de.investing.com

electroCore forecasts record revenue of approximately $31.8–32.0 million for 2025, representing about 26% growth versus 2024. For Q4 2025 the company expects revenue of roughly $9.0–9.2 million, an increase of about 30% year‑over‑year. At year-end electroCore had cash and marketable securities of around $11.6 million. The company sells non-invasive bioelectronic products such as gammaCore and Quell and has announced a detailed operational and financial update for its conference call in March 2026. » More on de.investing.com

electroCore elected Dr. Thomas J. Errico, co‑founder and former chair of the nominations and governance committee, as its new chairman of the board. He succeeds Peter Cuneo, who will leave the board on September 2, 2025 and will remain with the company as a strategic advisor. The company continues to focus on its bioelectronic products such as gammaCore, Quell and Truvaga; Q2 revenue rose 20% to $7.4 million despite a net loss of $3.7 million (−$0.44 per share). electroCore reports a high gross margin of 85.5% and annual revenue growth of 30%, but the stock has fallen sharply over the past six months and is rated as undervalued by analysts. » More on de.investing.com